A phase I/II study of induction therapy with topotecan, mitoxantrone and etoposide in relapsed/refractory acute myeloid leukemia (AML), myeloid blast crisis and high risk myelodysplastic syndromes (MDS).

被引：0
|
作者：
Nand, S [1 ]
Godwin, J [1 ]
White, C [1 ]
Beltran, O [1 ]
Stiff, P [1 ]
机构：
[1] Loyola Univ, Med Ctr, Maywood, IL 60153 USA
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4649
引用
收藏
页码：214B / 214B
页数：1
相关论文
共 50 条
  • [31] Efficacy of mitoxantrone and etoposide in patients with acute myeloid leukemia refractory to initial standard induction therapy
    Sehgal, Rajesh
    McHayleh, Wassim
    Natale, James
    Raptis, Anastasios
    Agha, Mounzer
    Redner, Robert L.
    Richard, Gene
    Welsh, Ann
    Foon, Kenneth A.
    Boyiadzis, Michael
    BLOOD, 2007, 110 (11) : 164B - 164B
  • [32] Decitabine As Induction Therapy For Median-To-High-Risk Myelodysplastic Syndromes(MDS) and Acute Myeloid Leukemia(AML) Before Allogeneic Stem Cell Transplantation
    Zhou, Lin
    Wu Depei
    Fu, Chengcheng
    Sun, Aining
    Qiu, Huiying
    Jin, Zhengming
    Tang, XiaoWen
    Han, Yue
    Ma, Xiao
    He, Guangsheng
    BLOOD, 2013, 122 (21)
  • [33] Phase I/II study of vosaroxin and decitabine in older patients (pts) with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
    Daver, Naval Guastad
    Kantarjian, Hagop M.
    Pierce, Sherry
    Brandt, Mark
    Dinardo, Courtney Denton
    Pemmaraju, Naveen
    Vaughan, Kenneth
    Garcia-Manero, Guillermo
    Jabbour, Elias
    Borthakur, Gautam
    Kadia, Tapan M.
    Cortes, Jorge E.
    Craig, Adam
    Ravandi, Farhad
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [34] Update of a phase I study of sorafenib in patients with refractory/relapsed acute myeloid leukemia or high-risk myelodysplastic syndrome
    Delmonte, John, Jr.
    Kantarjian, Hagop M.
    Andreef, Michael
    Faderl, Stefan
    Wright, John J.
    Zhang, Weiguo
    Konopleva, Marina
    Verstovsek, Srdan
    Borthakur, Gautam
    Ravandi, Farhad
    Cortes, Jorge
    BLOOD, 2007, 110 (11) : 272A - 273A
  • [35] Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML)
    Zeidner, Joshua F.
    Vincent, Benjamin G.
    Ivanova, Anastasia
    Foster, Matthew
    Coombs, Catherine C.
    Jamieson, Katarzyna
    Van Deventer, Hendrik
    Scibilia, Richard
    Blanchard, Laura
    Frank, Cassiopeia
    Gallagher, Sean
    Matson, Melissa
    Pepin, Katherine
    Vaught, Lori
    Vogler, Nancy
    Gojo, Ivana
    Luznik, Leo
    Serody, Jonathan S.
    BLOOD, 2017, 130
  • [36] Phase 1 Trial of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)
    Anwar, Asma
    Halpern, Anna B.
    Othus, Megan
    Scott, Bart L.
    Hendrie, Paul C.
    Becker, Pamela S.
    Perdue, Andrea M.
    Smith, Heather A.
    Chen, Tara L.
    Buckley, Sarah A.
    Orlowski, Kaysey F.
    Powell, Morgan A.
    Estey, Elihu H.
    Walter, Roland B.
    BLOOD, 2015, 126 (23)
  • [37] Twice Daily Fludarabine and Cytarabine Combination (BID-FA) Is Effective in Pts with De Novo Acute Myeloid Leukemia (AML), Relapsed/Refractory (R/R) AML, High-Risk Myelodysplastic Syndromes (MDS), and Blast Phase Chronic Myeloid Leukemia (CML-BP)
    Ghanem, Hady
    Kantarjian, Hagop M.
    Ravandi, Farhad
    Cortes, Jorge E.
    Pemmaraju, Naveen
    Faderl, Stefan
    Dellasala, Sara E.
    O'Brien, Susan M.
    Burger, Jan A.
    Borthakur, Gautam
    Kadia, Tapan M.
    Quintas-Cardama, Alfonso
    Brandt, Mark
    Pierce, Sherry A.
    Garcia-Manero, Guillermo
    Jabbour, Elias J.
    BLOOD, 2012, 120 (21)
  • [38] Rigosertib activity in patients with a myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) relapsed or refractory to hypomethylating agents
    Navada, S. C.
    Odchimar-Reissig, R.
    Reddy, E. P.
    Demakos, E. P.
    Holland, J. F.
    Wilhelm, F.
    Silverman, L. R.
    LEUKEMIA RESEARCH, 2013, 37 : S146 - S146
  • [39] Phase I study of clofarabine plus Idarubicin and Clofarabine plus Idarubicin plus Cytarabine (ARA-C) in patients (PTS) with relapsed and primary refractory acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and myeloid blast phase of chronic myeloid leukemia (CML).
    Faderl, S
    Ferrajolil, A
    Wierda, W
    Verstovsek, S
    Ravandi-Kashani, F
    Garcia-Manero, G
    Estey, E
    Thomas, DA
    Kornblau, S
    Kwari, M
    Gandhi, V
    Kantarjian, HM
    BLOOD, 2004, 104 (11) : 501A - 501A
  • [40] Phase II study of fludarabine, carboplatin, and topotecan with thalidomide (FCTT) for patients with relapsed/refractory or secondary acute myelogenous leukemia, chronic myeloid leukemia and advanced myelodysplastic syndromes.
    Barr, PM
    Koc, ON
    Tse, W
    Lazarus, HM
    Meyerson, HJ
    Cooper, BW
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 592S - 592S
12345